Veritas In Silico Inc. [130A.T]
TOKYO, Apr 13 (Pulse News Wire) – Veritas In Silico (130A.T) announced today that its collaboration agreement with Takeda Pharmaceutical Company Limited, which was established on June 19, 2023, for joint drug discovery research focused on mRNA-targeted small molecule medicines, has concluded successfully as of April 13, 2026. The company stated that while the termination of the collaboration will have limited impact on its operations, there are no anticipated changes to the previously disclosed fiscal year 2026 December quarter performance forecasts announced on February 15, 2026.
Both companies plan to continue discussions on potential future applications of the knowledge gained during the collaboration. In addition, Veritas In Silico emphasized that it will promptly disclose any further significant developments related to this matter.
🟢 Confidence: High AI-translated content.